New York and California are stockpiling alternative abortion pill misoprostol

New York and California are stockpiling alternative abortion pill misoprostol


Pills of Misoprostol, used to terminate early pregnancies, are displayed in a pharmacy in Provo, Utah, May 12, 2022.

George Frey | Reuters

New York and California are stockpiling massive quantities of an alternative abortion medication in case a federal judge’s order suspending the Food and Drug Administration’s approval of the main drug mifepristone goes into effect later this week.

New York Gov. Kathy Hochul on Tuesday ordered the state health department to immediately start purchasing 150,000 doses of misoprostol, a five-year supply of the pill. Hochul’s announcement comes a day after Gov. Gavin Newsom said California has secured 2 million pills of misoprostol.

Medication abortions are the most common way to terminate a pregnancy the U.S. Patients typically use a two drug-regimen in which mifepristone is taken first, followed by misoprostol. The second pill is used as a standalone abortion medication in parts of the world.

Misoprostol is FDA approved to treat gastric ulcers, so it will remain on the market if U.S. District Judge Matthew Kacsmaryk’s order suspending mifepristone takes effect at 12 a.m. central time on Saturday.

“One judge in Amarillo, Texas thinks he knows better than thousands of doctors and scientists and experts. And not to mention the countless women who’ve used this medication safely for decades,” Hochul said during a press conference with Planned Parenthood’s New York chapter Tuesday.

“This isn’t just an attack on abortion, it’s an attack on democracy. Courts have never before revoked a science backed decision made by the FDA,” the governor said.

CNBC Health & Science

Read CNBC’s latest global health coverage:

Hochul said she is working with New York’s legislature to require private insurers to cover misoprostol when it is prescribed off-label for abortions.

The Justice Department and Danco Laboratories, the distributor of mifepristone, have asked the U.S. 5th Circuit Court of Appeals to block Kacsmaryk’s ruling by noon Thursday.

The World Health Organization and the American College of Obstetricians and Gynecologists recommend misoprostol as a standalone abortion medication when the two-drug regimen is not available. But misoprostol is not as effective when it is used on its own, according to obstetricians and gynecologists.

The FDA has approved the two-drug abortion regimen through the 10th week of pregnancy. Mifepristone stops the pregnancy from developing further by blocking a hormone called progesterone. Misoprostol induces contractions that empty the uterus.

Patients take 200 milligrams of mifepristone by mouth on day one, and then take 800 micrograms of misoprostol in the cheek pouch 24 to 48 hours later, according to the FDA’s label.



Source

Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure
Health

Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure

The office building of international biopharmaceutical company AstraZeneca. Cfoto | Future Publishing | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. President Donald Trump has been pressuring pharmaceutical companies to lower U.S. drug […]

Read More
Trump’s pharmaceutical tariffs could affect some drugmakers more than others
Health

Trump’s pharmaceutical tariffs could affect some drugmakers more than others

Medications are stored on shelves at a pharmacy on May 12, 2025 in Los Angeles, California. Eric Thayer | Getty Images President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and the duties may have a bigger impact on some drugmakers than others, according to some […]

Read More
Merck plans  billion cost cuts by end of 2027, narrows full-year outlook
Health

Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook

Merck & Co. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Tuesday, April 8, 2025. Michael Nagle | Bloomberg | Getty Images Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches […]

Read More